610 results on '"Meads, David"'
Search Results
52. Recruiting to surgical trials in the emergency setting: using a mixed methods study to understand clinician and patient perspectives
53. Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
54. Improving access to medicines to support palliative care at home: challenges and opportunities
55. The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial
56. Patient choice in colorectal cancer treatment – A systematic review and narrative synthesis of attribute‐based stated preference studies
57. Patient and carer access to medicines at end of life: the ActMed mixed-methods study
58. Can We Rely on the Dermatology Life Quality Index as a Measure of the Impact of Psoriasis or Atopic Dermatitis?
59. Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
60. A biomarker enrichment trial of anti-EGFR agents in right primary tumor location (rPTL), RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC): ARIEL (ISRCTN11061442).
61. Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial
62. Cancer patients’ needs assessment in primary care: study protocol for a cluster randomised controlled trial (cRCT), economic evaluation and normalisation process theory evaluation of the needs assessment tool cancer (CANAssess)
63. Development and validation of the living with chronic obstructive pulmonary disease questionnaire
64. COPD and Asthma Fatigue Scale (CAFS): Development and Psychometric Assessment
65. International Development of the Patient-Reported Outcome Indices for Multiple Sclerosis (PRIMUS)
66. International Development of the Unidimensional Fatigue Impact Scale (U-FIS)
67. Effects of Method of Translation of Patient-Reported Health Outcome Questionnaires: A Randomized Study of the Translation of the Rheumatoid Arthritis Quality of Life (RAQoL) Instrument for Sweden
68. Development and validation of the Asthma Life Impact Scale (ALIS)
69. Modelling decay in effectiveness for evaluation of behaviour change interventions: a tutorial for public health economists
70. Pain self-management interventions for community-based patients with advanced cancer: a research programme including the IMPACCT RCT
71. Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials
72. Do home adaptation interventions help to reduce emergency fall admissions? A national longitudinal data-linkage study of 657,536 older adults living in Wales (UK) between 2010 and 2017
73. The Development of the Herpes Symptom Checklist and the Herpes Outbreak Impact Questionnaire
74. In a dark time: Development, validation, and correlates of the Durham hypnagogic and hypnopompic hallucinations questionnaire
75. Constructing Indirect Utility Models: Some Observations on the Principles and Practice of Mapping to Obtain Health State Utilities
76. Does a health crisis change how we value health?
77. What factors affect patients’ ability to access healthcare? An overview of systematic reviews
78. The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma
79. Additional file 2 of Changing the eligibility criteria for welfare payments at the end of life – a budget impact analysis for England and Wales
80. sj-docx-2-qhr-10.1177_1049732321994791 – Supplemental material for Making Public Involvement in Research More Inclusive of People With Complex Speech and Motor Disorders: The I-ASC Project
81. Additional file 1 of Changing the eligibility criteria for welfare payments at the end of life – a budget impact analysis for England and Wales
82. sj-docx-3-qhr-10.1177_1049732321994791 – Supplemental material for Making Public Involvement in Research More Inclusive of People With Complex Speech and Motor Disorders: The I-ASC Project
83. Additional file 1 of The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma
84. sj-docx-1-qhr-10.1177_1049732321994791 – Supplemental material for Making Public Involvement in Research More Inclusive of People With Complex Speech and Motor Disorders: The I-ASC Project
85. Additional file 2 of The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma
86. Making public involvement in research more inclusive of people with complex speech and motor disorders: the I-ASC project
87. The decision-making process in recommending electronic communication aids for children and young people who are non-speaking: the I-ASC mixed-methods study
88. Dynamic Frailty Assessment in Transplant Non-Eligible Newly Diagnosed Myeloma Patients: Initial Data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): A Frailty-Adjusted Therapy Study
89. Health-Related Quality of Life (HRQoL) in Patients with Genetic Standard and High-Risk Disease at Trial Entry: A Cross-Sectional Analysis of RADAR (UK-MRA Myeloma XV)
90. High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study
91. RADAR Trial: MRD Response Adapted Trial for Newly Diagnosed Transplant Eligible Myeloma Patients
92. Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study
93. United States Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)
94. Rasch analysis and item reduction of the hypomanic personality scale
95. 'The defence sector must invest in its workforce to truly harness the benefits of new technology'
96. MOESM1 of What factors affect patients’ access to healthcare? Protocol for an overview of systematic reviews
97. Additional file 1 of Supporting patient access to medicines in community palliative care: on-line survey of health professionals’ practice, perceived effectiveness and influencing factors
98. Cross-Cultural Inequivalence of Dermatology-Specific Health-Related Quality of Life Instruments in Psoriasis Patients
99. Adaptation of the rheumatoid arthritis quality of life scale for Estonia
100. The decision-making process in recommending electronic communication aids for children and young people who are non-speaking: the I-ASC mixed-methods study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.